MAP2K5 and cancer: In contrast to the RAF/MEK/ERK pathway, activating mutations in components of the MEK5/ERK5 pathway are rare throughout the cancer entities and activation of the MEK5/ERK5 pathway in tumors is associated with overexpression of single components of the ERK5 pathway or deregulated receptor tyrosine kinase activity [112].